At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 7 enrolled
Drug / intervention
[18F]MNI-815 (MNI-815)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies
In Brief
A Early Phase 1 clinical trial evaluating [18F]MNI-815 (MNI-815) for Alzheimer's Disease (AD) and 3 related conditions. Completed, enrolled 7 participants across 1 site.
Detailed Summary
The overall goal of this imaging trial is to characterize \[18F\]MNI-815, a PET radioligand for imaging Tau.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
CountriesUnited States
CollaboratorsLantheus Biosciences Ltd.
Timeline
Early Ph 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMay 2015
First PostedAug 2015
Primary CompletionJul 2016
Study CompletionAug 2016
TodayJul 2026
First PostedAug 24, 2015
Enrollment StartMay 1, 2015
Primary CompletionJul 1, 2016
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.9 years ago
Interventions
[18F]MNI-815 (MNI-815)drug
All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.